Equities
Health CareMedical Equipment and Services
  • Price (USD)307.19
  • Today's Change-0.045 / -0.01%
  • Shares traded189.53k
  • 1 Year change-17.38%
  • Beta1.2058
Data delayed at least 15 minutes, as of Mar 03 2026 15:41 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Waters Corporation is a global life sciences and diagnostics company. The Company offers analytical instruments, separations technologies, and software, serving life, materials, food, and environmental sciences. Its segments include Waters and TA. The Company primarily designs, manufactures, sells and services high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and comprehensive post-warranty service plans. The Company designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments through its TA Instruments (TA) product line. The Company is also a developer and supplier of advanced software-based products that interface with the Company’s instruments, as well as other manufacturers’ instruments.

  • Revenue in USD (TTM)3.17bn
  • Net income in USD642.63m
  • Incorporated1991
  • Employees7.90k
  • Location
    Waters Corp34 MAPLE STMILFORD 01757-3604United StatesUSA
  • Phone+1 (302) 658-7581
  • Fax+1 (302) 655-5049
  • Websitehttps://www.waters.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
WAT:NYQ since
announced
Transaction
value
Optofluidics IncDeal completed20 May 202520 May 2025Deal completed-14.32%--
Data delayed at least 15 minutes, as of Mar 03 2026 15:41 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cooper Companies Inc4.09bn374.90m16.37bn15.00k44.792.0021.774.001.871.8720.4642.060.33121.715.29272,826.703.038.043.328.8665.5466.019.1624.661.136.320.23320.20495.0610.98-4.449.483.15--
Hologic Inc4.13bn543.80m16.84bn7.07k31.313.2120.074.082.412.4118.2823.510.46082.576.79583,663.406.0711.226.8212.8556.5160.2013.1821.993.3215.760.32460.001.741.66-28.35-12.69-0.5168--
Insulet Corp2.71bn247.10m17.28bn5.40k70.1211.4051.186.383.503.5037.8621.530.86281.746.14501,518.507.877.149.758.5171.6368.729.1310.062.1546.910.38520.0030.7324.53-40.93105.155.67--
West Pharmaceutical Services Inc3.07bn493.70m18.10bn10.80k36.985.7027.815.896.796.7942.2844.110.77694.805.40284,638.9012.1115.2414.2918.1935.9137.8915.5918.672.34--0.061410.136.257.440.2037.3610.395.51
Zimmer Biomet Holdings Inc8.23bn704.60m19.47bn17.00k28.061.5310.822.363.553.5541.4464.950.37031.105.17484,211.803.173.033.583.4669.7171.018.569.101.104.710.371829.267.206.08-21.98--9.260.00
Illumina Inc4.34bn850.00m20.32bn8.60k24.267.4718.144.685.485.4827.8817.800.67092.615.34505,000.0013.13-10.1517.32-12.1566.6165.3919.57-23.181.7215.790.4221---0.66336.04169.505.32-4.77--
Steris PLC5.83bn708.66m24.30bn17.79k34.483.4020.304.177.197.1859.0972.930.56584.926.12327,662.406.915.047.595.5144.1143.7512.2110.691.7520.990.209437.516.2412.4910.648.4011.528.99
DexCom Inc4.66bn836.30m28.40bn11.00k35.7110.3426.106.092.072.0711.507.140.7273.024.20423,818.2013.048.8521.5812.5862.0963.9217.9414.211.59--0.3204--15.6019.3345.148.7512.81--
Veeva Systems Inc3.08bn860.33m29.83bn7.29k35.294.2433.149.685.145.1418.4142.840.4234--9.15422,472.4011.8311.3313.5014.3575.6772.6027.9323.96----0.000.0016.2019.9935.8418.8536.56--
Waters Corp3.17bn642.63m30.14bn7.90k28.567.1435.479.5210.7610.7653.0143.010.65742.464.05400,669.1013.3517.0316.9121.5159.2859.0020.3022.401.2715.810.35460.006.996.000.75184.26-8.14--
Agilent Technologies Inc7.07bn1.29bn33.41bn18.10k26.094.8421.244.734.534.5324.8124.440.57143.264.96390,331.5010.4311.4412.5113.6752.5353.2518.2618.821.5919.120.326820.766.735.411.0912.6327.887.10
GE HealthCare Technologies Inc20.63bn2.09bn36.53bn54.00k17.613.5213.371.774.554.5545.0322.770.58935.934.31381,944.406.156.708.469.2539.9840.4410.4410.491.139.970.48661.854.843.744.570.755813.23--
Resmed Inc5.40bn1.49bn37.50bn10.60k25.445.9322.186.9510.1210.1236.7543.390.69012.345.53509,256.5019.0015.3321.9417.7660.8557.2927.5321.962.32--0.09528.949.8411.7237.2017.64-1.021.69
Data as of Mar 03 2026. Currency figures normalised to Waters Corp's reporting currency: US Dollar USD

Institutional shareholders

45.58%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 20256.88m11.55%
Fundsmith LLPas of 31 Dec 20254.70m7.90%
BlackRock Fund Advisorsas of 31 Dec 20253.45m5.79%
SSgA Funds Management, Inc.as of 31 Dec 20252.68m4.51%
AllianceBernstein LPas of 31 Dec 20252.07m3.47%
Massachusetts Financial Services Co.as of 31 Dec 20251.94m3.26%
Geode Capital Management LLCas of 31 Dec 20251.59m2.68%
Mawer Investment Management Ltd.as of 31 Dec 20251.30m2.18%
Janus Henderson Investors US LLCas of 31 Dec 20251.29m2.16%
Veritas Asset Management LLPas of 31 Dec 20251.24m2.08%
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.